Linked Life Data

2969098

Source:http://linkedlifedata.com/resource/pubmed/id/2969098

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
1988-8-12
pubmed:abstractText
SIN-1, a new anti-anginal compound, has been the object of extensive clinical and experimental research work. It has been injected into the coronary arteries in more than 1,000 patients, enabling its effects on coronary circulation to be studied without interference from its systemic effects. Contrary to dipyridamole or calcium channel blockers, SIN-1 dilates the main epicardial coronary vessels without blood steal. The dilatation it induces is rapid and prolonged, and its intensity is at least equivalent to that of nitroglycerin, nitrites and calcium inhibitors. Its action lasts longer than that of nitroglycerin. SIN-1 enables balloon inflation to be prolonged in percutaneous transluminal coronary angioplasty. It is effective in relieving coronary spasm and has a favourable effect on anterograde and collateral circulation. Haemodynamically, SIN-1 significantly reduces preload but has little effect on afterload; it does not alter left ventricular contractility and has no influence on peripheral resistance. Owing to its rapid and long-lasting dilating effect specifically on the epicardial coronary arteries, its effectiveness against coronary spasm and its lack of side-effects, SIN-1 is indicated for coronary arteriography and coronary spasms.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0755-4982
pubmed:author
pubmed:issnType
Print
pubmed:day
25
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1027-32
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
[SIN-1 in intracoronary administration].
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Review